Peapod Lane Capital LLC bought a new position in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 598,245 shares of the company's stock, valued at approximately $1,101,000. Nkarta comprises 1.2% of Peapod Lane Capital LLC's holdings, making the stock its 29th largest holding. Peapod Lane Capital LLC owned approximately 0.84% of Nkarta as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Sequoia Financial Advisors LLC bought a new position in shares of Nkarta during the 4th quarter valued at about $31,000. Thrivent Financial for Lutherans bought a new position in shares of Nkarta during the 4th quarter valued at about $258,000. American Century Companies Inc. lifted its holdings in shares of Nkarta by 8.8% during the 4th quarter. American Century Companies Inc. now owns 90,952 shares of the company's stock valued at $226,000 after purchasing an additional 7,378 shares in the last quarter. Sei Investments Co. bought a new position in shares of Nkarta during the 4th quarter valued at about $57,000. Finally, Samalin Investment Counsel LLC bought a new position in shares of Nkarta during the 4th quarter valued at about $211,000. Institutional investors own 80.54% of the company's stock.
Nkarta Stock Up 1.7%
NASDAQ:NKTX opened at $1.81 on Thursday. The firm has a market capitalization of $128.43 million, a price-to-earnings ratio of -1.20 and a beta of 0.70. Nkarta, Inc. has a twelve month low of $1.31 and a twelve month high of $8.23. The stock's 50 day moving average price is $1.82 and its two-hundred day moving average price is $1.96.
Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.01. As a group, analysts anticipate that Nkarta, Inc. will post -1.7 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on NKTX. HC Wainwright reiterated a "buy" rating and set a $18.00 price objective on shares of Nkarta in a report on Thursday, March 27th. Mizuho dropped their target price on Nkarta from $16.00 to $14.00 and set an "outperform" rating on the stock in a research report on Tuesday, June 10th. Stifel Nicolaus dropped their target price on Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th. Needham & Company LLC dropped their target price on Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Finally, William Blair reissued a "market perform" rating on shares of Nkarta in a research report on Thursday, May 15th. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $14.33.
Get Our Latest Stock Report on NKTX
About Nkarta
(
Free Report)
Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
Featured Articles
Want to see what other hedge funds are holding NKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nkarta, Inc. (NASDAQ:NKTX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nkarta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.
While Nkarta currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
